1-deoxynojirimycin has been researched along with Dengue Hemorrhagic Fever in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alonzi, DS; Beatty, PR; Buck, MD; Caputo, AT; Dwek, RA; Eddy, W; Enterlein, SG; Harris, E; Hill, ML; Ide, D; Iwaki, R; Kato, A; Khaliq, M; Kiappes, JL; Killingbeck, SS; Kinami, K; King, K; Miller, JL; Plummer, EM; Ramstedt, U; Sampath, A; Sayce, AC; Shresta, S; Tang, W; Treston, AM; Tyrrell, BE; Warfield, KL; Zitzmann, N | 1 |
1 other study(ies) available for 1-deoxynojirimycin and Dengue Hemorrhagic Fever
| Article | Year |
|---|---|
Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; Antibodies, Viral; Antibody-Dependent Enhancement; Antiviral Agents; Cells, Cultured; Chlorocebus aethiops; Clinical Trials as Topic; Dengue Virus; Disease Models, Animal; Drugs, Investigational; Endoplasmic Reticulum; Glycoside Hydrolase Inhibitors; Humans; Inhibitory Concentration 50; Mice; Monocytes; Receptors, Interferon; Serogroup; Severe Dengue; Vero Cells | 2016 |